4.7 Article

The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer

期刊

ANNALS OF SURGICAL ONCOLOGY
卷 -, 期 -, 页码 -

出版社

SPRINGER
DOI: 10.1245/s10434-023-13932-3

关键词

HIPEC; Epithelial ovarian cancer; Advanced ovarian cancer; Interval cytoreductive surgery; Recurrent ovarian cancer

向作者/读者索取更多资源

This study presents the results of an international consensus on HIPEC regimens for EOC, providing indications and suitable regimens for treatment. It also identifies areas for future research and offers recommendations for perioperative care.
Background and AimWe report the results of an international consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) regimens for epithelial ovarian cancer (EOC) performed with the following goals:To define the indications for HIPECTo identify the most suitable HIPEC regimens for each indication in EOCTo identify areas of future research on HIPECTo provide recommendations for some aspects of perioperative care for HIPECMethodsThe Delphi technique was used with two rounds of voting. There were three categories of questions: evidence-based recommendations [using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system with the patient, intervention, comparator, and outcome (PICO) method], an opinion survey, and research recommendations.ResultsSeventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41 & DEG;C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.ConclusionsThe results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据